age-related macular degeneration (AMD)

Extensive analysis confirms treat-and-extend regimens reliable for AMDIn patients with age-related macular degeneration managed by a treat-and-extend regimen, the visual acuity generally was maintained; lesion reactivation occurred frequently at about eight weeks; and longer induction phases between treatments was associated with worse outcomes.
Per aspera ad astra – Through hardships to the starsAccording to the latest data by the World Health Organization, there are approximately 36 million blind people in the world, and the numbers keep growing due to increasing population sizes in developing countries and rising life expectancies in developed nations.
Subretinal therapy offers promise of lighter treatment burden for AMDRGX-314 gene therapy offers patients the potential for a lower treatment burden with one subretinal injection of a gene therapy delivering an anti-vascular endothelial growth factor protein.
Using OCTA in optometric practice
Using OCTA in optometric practiceBy using OCTA technology, we are able to take better care of our patients with retinal disease, make smarter referrals, or be able to hold on to our patients, knowing a referral is not needed.
Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
Role of corticosteroids uncertain in AMD managementThere is no doubt that inflammation is a component of age-related macular degeneration (AMD), and yet the role of corticosteroid treatment in the management of eyes with AMD remains uncertain, said Marc de Smet, MD, PhD.
Ultra-widefield camera captures images from macula, far peripheryA recently released ultra-widefield fundus camera takes images in true color and captures high-resolution imagess rom the macula to the far periphery.
OCTA system offers exquisite views
OCTA system offers exquisite viewsA new high-density OCT angiography system (AngioVueHD, OptoVue) provides exquisite views of the retinal microvasculature without the need for injection of fluorescein dye.
Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progressAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.